STAT
DECEMBER 3, 2023
LONDON — The booming obesity market is attracting another player, as pharma giant Roche said Monday it was acquiring Carmot Therapeutics and the company’s line of weight loss drug candidates for $2.7 billion upfront. The deal for Carmot, which is based in Berkeley, Calif., includes additional milestone payments of up to $400 million.
Safe Biologics
DECEMBER 3, 2023
ASBM and GaBI Webinar Examines Policy Challenges to Interchangeable Biosimilars On November 30, ASBM and the Generics and Biosimilars Initiative (GaBI) hosted I nterchangeable Designation for Biosimilars- Ensuring Continuity of Patient Care: Upholding Interchangeability Status for Biosimilars. The webinar was the fourth in a series covering key health policy issues.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Med Ed 101
DECEMBER 3, 2023
Many institutions that pass medications need to be aware of when medications expire. The GLP-1 agonist class has been quickly expanding so we wanted to put together a storage chart to ensure that healthcare professionals and patients properly store their medications. In addition to the visual GLP-1 Agonist storage chart on this page, I’ve included […] The post GLP-1 Agonist Storage Chart – Free PDF appeared first on Med Ed 101.
Pharma in Brief
DECEMBER 3, 2023
This year marks the 30-year anniversary of the Patented Medicines (Notice of Compliance) Regulations ( Regulations ), introduced in 1993 to prevent patent infringement by linking the regulatory approval of generic or biosimilar drugs with the patent rights of innovators. Since their genesis, the Regulations have been the focal point of most of the pharmaceutical patent litigation in Canada.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
The Guardian - Pharmaceutical Industry
DECEMBER 3, 2023
Royal portraits | Viagra article | Losing sucks | Karlheinz Stockhausen | Hum improvement | Appalling apostrophes I’m confused. Is the £8m that Polly Toynbee reports is being spent by the government to send an “oak-framed portrait of the king” to every school going to encourage pupils to attend or have the reverse effect ( Too many pupils miss lessons, says Ofsted, and that’s right.
Drug Patent Watch
DECEMBER 3, 2023
This chart shows the drugs with the most patents in Spain. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.… The post Which pharmaceutical drugs have the most drug patents in Spain? appeared first on DrugPatentWatch - Make Better Decisions.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
pharmacy mentor
DECEMBER 3, 2023
Pharmacy Mentor and Tympa Health: Revolutionising Your Ear Health Services We are delighted to share exciting news about our recent collaboration with Tympa Health , a partnership that is set to reshape the landscape of earwax removal services in pharmacies. At Pharmacy Mentor, our commitment to advancing pharmacy services aligns seamlessly with Tympa Health’s cutting-edge approach to ear healthcare.
Pharmacy Joe
DECEMBER 3, 2023
In this episode, I’ll discuss whether diuretics are safe for reducing fluid balance in critically ill patients. Episode 875: The Safety of Diuretics to Reduce Fluid Balance in Critically Ill Patients Subscribe on iTunes , Android , or Stitcher Interest in fluid balance and the associated adverse effects in ICU patients has grown considerably over the last decade.
Express Pharma
DECEMBER 3, 2023
Following the news that AbbVie has agreed to buy biotech ImmunoGen , the maker of the FDA-approved ovarian cancer treatment Elahere, for $10.1 billion; Israel Stern, Oncology & Hematology Analyst at GlobalData, a leading data and analytics company, offers his view: “The news comes one day after AbbVie announced that it is preparing to seek accelerated approval for its own antibody-drug conjugate (ADC) telisotuzumab-vedotin, which has shown promising response rates in advanced non-small cell
Expert insights. Personalized for you.
335 
Let's personalize your content